Global Newsroom

^{_{CSL Behring Patient Zahra Khan, living with hereditary angioedema}}

Global Newsroom

Recent News Releases

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

Mar 27, 2023

CSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts

The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines WALTHAM, Mass., March 27, 2023 /PRNewswire/ -- Global biotechnology...

Recent News Releases

Email Alerts

CSL Behring

Apr 18, 2023

CSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe

Hizentra® is the first and only immune globulin (Ig) available in prefilled syringes, offering those living with Primary Immunodeficiency (PI) or Chronic Inflammatory Demyelinating Polyneuropathy...

Recent News Releases

Email Alerts

CSL Seqirus

May 21, 2023

CSL Seqirus’ $800m+ innovative vaccine and antivenom manufacturing facility in Australia reaches major construction milestone

Melbourne, Monday 22 May CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping...

Recent News Releases

Email Alerts

CSL Vifor

May 18, 2023

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus...

Read more news from CSL Vifor

Read all company news releases

Quick Links

Leadership Perspectives

Annual Reports

Photos and Logos